Pay in 4 interest-free payments of $7.32 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
We do not accept liability for misuse
Some plans cover obesity medications with prior authorization
GSBR-1290: While still in development, GSBR-1290 is another oral GLP-1 antagonist used to manage chronic obesity and type 2 diabetes compared to Orforglipron
Studies show it promotes angiogenesis and collagen deposition at injury sites
TEAEs occurred in 5/6 (83.3%) participants in each PG-102 cohort and 4/6 (66.7%) in placebo
La resistencia a la insulina severa, el sndrome de ovario poliqustico (SOP), el hipotiroidismo no controlado, o el uso de medicamentos que promueven ganancia de peso (como algunos antipsicticos, antidepresivos o corticosteroides) pueden contrarrestar los efectos de los GLP-1
US$ 20.25
US$ 20.45
US$ 25.05
US$ 20.54
US$ 20.81
